A versatile plasmid platform for auxotrophic complementation in attenuated Mycobacterium bovis BCG
Authors:
Open Access
- 28 April 2026
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 679
Abstract
Background: Mycobacterium bovis BCG is widely used as a vaccine vector due to its safety, genetic stability, and immunomodulatory properties. However, current expression systems for BCG transformation rely on antibiotic resistance genes, raising biosafety concerns. Therefore, alternative strategies—such as the use of auxotrophic strains—are highly desirable. Our group previously employed BioBrick™ technology to construct the pUP500 plasmid series containing various mycobacterial promoters. We engineered these plasmids for the auxotrophic complementation of BCG ΔLeuD, a leucine-auxotrophic strain, using an antibiotic-free and BioBrick™-compatible approach. Methods and Results: The auxotrophic complementation cassette pAN- leuD was cloned into pUP500 plasmids. Subsequently, the egfp gene was inserted downstream of the promoters, the kanamycin resistance gene was removed, and fluorescence was assessed by flow cytometry, qPCR and confocal microscopy in BCG grown in 7H9 medium and inside macrophages. Auxotrophic complementation was confirmed by growth of transformants in non-selective medium and analysis of leuD expression, and plasmid stability was evaluated along six BCG generations. Strains harboring plasmids containing the pAN and HspX promoters exhibited stronger fluorescence levels both in vitro and within macrophages. In contrast, the 18 kDa promoter demonstrated marked activation specifically in the intracellular environment, driving robust gene expression inside macrophages. These expression patterns were significantly higher compared to strains carrying the Ag85B or Hsp60 promoters, as well as to the negative control. Except for the Hsp60 construct, all plasmids exhibited robust in vitro stability across six consecutive passages, supporting their potential as reliable expression systems for heterologous antigens in therapeutic and vaccine applications. Conclusions: We developed five BioBrick™-compatible plasmids with distinct promoters for auxotrophic complementation and antigen expression in BCG ΔLeuD, eliminating the need for antibiotic-based selection. This standardized plasmid series reduces vector-related variability in comparative studies and provides a diverse promoter repertoire that may enhance the stability and efficacy of recombinant BCG ΔLeuD strains, representing a valuable advancement for prophylactic and therapeutic vaccine development.Keywords
Funding Information
- Universidade Federal de Pelotas
This publication has 27 references indexed in Scilit:
- A standardized BioBrick toolbox for the assembly of sequences in mycobacteriaTuberculosis, 2019
- Mycobacterium tuberculosis Reporter Strains as Tools for Drug Discovery and DevelopmentIUBMB Life, 2018
- Recombinant BCG vaccines: molecular features and their influence in the expression of foreign genesApplied Microbiology and Biotechnology, 2017
- Different behaviours of promoters in Mycobacterium tuberculosis H37Rv and H37RaWorld Journal of Microbiology and Biotechnology, 2015
- Auxotrophic recombinant Mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitroApplied Microbiology and Biotechnology, 2012
- Available methods for assembling expression cassettes for synthetic biologyApplied Microbiology and Biotechnology, 2012
- Optimized compatible set of BioBrick™ vectors for metabolic pathway engineeringApplied Microbiology and Biotechnology, 2011
- Recombinant Mycobacterium bovis BCGVaccine, 2009
- Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in Mycobacterium bovis BCGTuberculosis, 2007
- Expression of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strainsTuberculosis, 2002